Educational Announcement
The Upcoming FDA Changes & How Pure Rx Can Help You Navigate them
Aug. 6th, 2024, 1:50 PM CST / Updated Aug. 6th, 2024, 5:00 PM CST
By Faraz Khan - Cellular/Molecular Biologist & Geneticist
Are you aware of the upcoming changes to the FDA Drug Shortage list? These revisions could significantly impact your supply chain and ability to obtain peptides like Semaglutide and Tirzepatide from your current supplier.
What’s Changing?
The FDA is updating its Drug Shortage list, and peptides currently on the list will soon be removed.
This removal will prevent 503a and 503b Compounding Pharmacies from manufacturing and distributing these critical products.
Many practices will need to find alternative sources for these essential treatments.
Why It Matters:
Disruption to your supply chain could affect your ability to meet client needs.
Compliance risks increase as you seek new, unproven suppliers.
Pure Rx is Here to Help:
WHO/GMP and ISO U001:2008 Approved: Our cancer research facility and laboratory are fully compliant and will not be affected by these FDA changes.
Quality Assurance: We provide Certificates of Analysis (COAs) that verify the 99% purity of our peptides and biologics.
100% U.S. Based Manufacturing: All our products are manufactured and distributed within the United States, ensuring strict regulatory compliance.
Cost-Effective Solutions: We guarantee that we can beat your current pricing, offering you not just quality but value.
Why Choose Pure Rx?
Free White Labeling: Enhance your brand with our customized product solutions.
Free Delivery: We ensure timely and cost-free delivery of your orders.
Expert Guidance: We can help you navigate through these regulatory changes with minimal disruption to your business.
Let’s Talk
Don't let these changes catch you off guard. Schedule a consultation with Pure Rx today and discover how we can help you continue providing top-tier care to your clients without interruption.
Contact us now to secure your supply chain and protect your practice.
